<?xml version="1.0" encoding="UTF-8"?>
<ref id="bib144">
 <element-citation publication-type="journal" id="sref144">
  <person-group person-group-type="author">
   <name>
    <surname>Wang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Hu</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Xu</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Zhang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Musharrafieh</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Hau</surname>
    <given-names>R.K.</given-names>
   </name>
   <name>
    <surname>Ma</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Wang</surname>
    <given-names>J.</given-names>
   </name>
  </person-group>
  <article-title>In vitro pharmacokinetic optimizations of AM2-S31N channel blockers led to the discovery of slow-binding inhibitors with potent antiviral activity against drug-resistant influenza A viruses</article-title>
  <source>J. Med. Chem.</source>
  <volume>61</volume>
  <year>2018</year>
  <fpage>1074</fpage>
  <lpage>1085</lpage>
  <pub-id pub-id-type="doi">10.1021/acs.jmedchem.7b01536</pub-id>
  <pub-id pub-id-type="pmid">29341607</pub-id>
 </element-citation>
</ref>
